Drugs / rHPIV3cp45
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01254175 | Dec 2010 → Feb 2012 | parainfluenza virus type 3 infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01021397 | Nov 2009 → Dec 2011 | Paramyxoviridae infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00308412 | Jun 2006 → Apr 2010 | Paramyxoviridae infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rHPIV3cp45 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00308412 ↗ |
| Modality | Vaccine | “live recombinant attenuated intranasal HPIV3 vaccine” NCT00308412 ↗ |
| Route | Intranasal | “Immunizations will be given as nose drops.” NCT00308412 ↗ |